In conclusion, plasma biomarkers Lp-PLA2 activity and mass were found to be useful markers of PAD risk during long-term follow-up together with the established biomarker CRP, implying that they might also be used as predictors for subclinical atherosclerosis and atherosclerotic disease. This evidence concerns the gene CRP and peripheral arterial disease.